Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically and serologically confirmed multiple myeloma meeting one of the following criteria:~  * High-risk myeloma, defined as symptomatic International Staging System (ISS) stage 2 or 3 multiple myeloma~ * Soft-tissue involvement with myeloma in the form of a soft-tissue plasmacytoma~ * Extension of a plasmacytoma into soft tissues~ * Primary resistant myeloma, defined as unchanged or progressive myeloma despite two courses of standard treatment~* No ISS stage 1 multiple myeloma without soft-tissue involvement~* No smoldering myeloma~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy \> 16 weeks~* Absolute granulocyte count ≥ 1,500/mm³ (unless low granulocyte counts are due to multiple myeloma)~* Platelet count ≥ 100,000/mm³ (unless low platelet counts are due to multiple myeloma)~* Bilirubin ≤ 2.0 mg/dL~* AST and ALT \< 3 times upper limit of normal (ULN)~* Alkaline phosphatase \< 3 times ULN~* LVEF ≥ 50% by MUGA or ECHO~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception 4 months prior to, during, and for 4 weeks after completion of study treatment~* No active thromboembolic disease on anticoagulation~* No active angina or myocardial infarction within the past 6 months~* No pre-existing neuropathy or sensory or neuropathic pain ≥ grade 2~* No concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix~  * Prior malignancies that have not required antitumor treatment within the past 24 months allowed~ * Patients with a history of stage I or II (T1a/b) prostate cancer (detected incidentally at transurethral resection of prostate \[TURP\] and comprising \< 5% of resected tissue) allowed if the prostate-specific antigen has remained normal since TURP~* No known HIV positivity or AIDS-related illness~* No other medical condition or reason that, in the opinion of the investigator, would preclude study compliance~* No history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or to components of pegylated doxorubicin hydrochloride liposome, bortezomib, boron, or mannitol~PRIOR CONCURRENT THERAPY:~* Prior radiotherapy allowed~* No more than 2 courses of prior initial chemotherapy for multiple myeloma~* No prior bortezomib~* No prior high-dose steroids (not including taper) for more than 1 month in duration for emergent indications, such as hypercalcemia or life-threatening lesions (e.g., spinal cord compromise) (in high-risk patients)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Combination therapy (Type: EXPERIMENTAL): Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.

Based on this trial design, predict the completion outcome and termination type (if applicable).